Meta-analysis found that the patients whose cancer tissue was positive for CD133 expression showed a worse OS than those with negative ones (OR = 2.25, 95% CI: 1.24–4.07, P = 0.008, random model), suggesting that CD133 could be an independent prognostic factor in NSCLC patients (Figure 2). This evidence concerns the gene PROM1 and cancer.